Contact Us Search
CA Department of Insurance

Whistleblower lawsuit results in $1.1 million settlement with Novo Nordisk Inc.

News: 2017 Press Release

For Release: September 5, 2017
Media Calls Only: 916-492-3566
Email Inquiries:
Whistleblower lawsuit results in $1.1 million settlement with Novo Nordisk Inc.

SACRAMENTO, Calif. — Insurance Commissioner Dave Jones reached a $1.1 million settlement with pharmaceutical company Novo Nordisk Inc. over allegations that Novo Nordisk's drug Victoza was extensively promoted for uses not approved of by the Food and Drug Administration, which violates the Insurance Frauds Prevention Action. The settlement stems from allegations in a whistleblower lawsuit filed by Peter Dastous, an Endocrinology Diabetes Care Specialist formerly employed by Novo Nordisk.

Victoza was approved by the FDA for the treatment of adults with Type II diabetes. Dastous, represented by Phillips & Cohen, LLP, alleged Novo Nordisk inappropriately marketed Victoza for use with pediatric patients with Type II diabetes and adult patients who did not have Type II diabetes. The FDA did not approve the use of Victoza for the treatment of pediatric patients, due to the lack of pediatric studies.

"Illegal and unethical pharmaceutical marketing practices puts patient health at risk in exchange for higher profits," said Insurance Commissioner Dave Jones. "The alleged marketing of the drug Victoza to pediatric patients with Type II diabetes and adults without Type II diabetes not only violated patients' trust but it's also against the law."

In approving Victoza, the FDA issued a warning that the medication had a risk of tumors caused by Medullary Thyroid Carcinoma (MTC). Victoza's marketing was inconsistent with the labeling instructions and warnings concerning the risk of MTC tumors.

The settlement also addresses allegations that Novo Nordisk officials provided its sales force with information used to create a false or misleading impression, which minimized the importance of the FDA warning concerning the risk of tumors caused by MTC. Certain Novo Nordisk sales representatives allegedly made false or misleading statements designed to circumvent the requirements of the warning issued through the FDA.

# # #

Media Notes:

  • This whistleblower lawsuit was filed by Peter Dastous, an   Endocrinology Diabetes Care Specialist ("EDCS") responsible for the sale of Novo's diabetes products in South Carolina and Northern Georgia, who is represented by Erika Kelton and Larry Zoglin of Phillips & Cohen LLP. Commissioner Jones joined the whistleblower in the lawsuit.
  • As required by the state's insurance whistleblower law, Novo Nordisk's settlement payment will be divided between the whistleblowers and the State of California. The state will receive $550,000, to be used to enhance the investigation and prevention of insurance fraud.
  • Novo Nordisk did not admit to wrongdoing in the settlement agreement.
  • This settlement is contemporaneous with other federal and state settlements.

Other examples of CDI qui tam cases:

The California Department of Insurance, established in 1868, is the largest consumer protection agency in California. Insurers collect $289 billion in premiums annually in California. Since 2011 the California Department of Insurance received more than 1,000,000 calls from consumers and helped recover over $469 million in claims and premiums. Please visit the Department of Insurance web site at Non-media inquiries should be directed to the Consumer Hotline at 800.927.HELP or 213.897.8921. Telecommunications Devices for the Deaf (TDD), please dial 800.482.4833.

Font Size: Translate: Español